PROMETHEUS BIOSCIENCES
Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rig... hts to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.
PROMETHEUS BIOSCIENCES
Social Links:
Industry:
Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
1995-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.prometheusbiosciences.com
Total Employee:
501+
Status:
Active
Contact:
858-824-0895
Email Addresses:
[email protected]
Total Funding:
951.84 M USD
Technology used in webpage:
Domain Not Resolving Mobile Non Scaleable Content Cloudflare Hosting Nginx Person Schema Amazon Virginia Region Apache 2.4 Amazon Route 53 Java EE OpenSSL
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cypress Bioscience
Cypress Bioscience provides therapeutics and personalized medicine services to facilitate improved and individualized patient care.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Private Equity Round - Prometheus Biosciences
Cedars Sinai
Cedars Sinai investment in Private Equity Round - Prometheus Biosciences
Nestlé
Nestlé investment in Private Equity Round - Prometheus Biosciences
AGI Partners
AGI Partners investment in Private Equity Round - Prometheus Biosciences
Cormorant Capital
Cormorant Capital investment in Private Equity Round - Prometheus Biosciences
RTW Investments
RTW Investments investment in Private Equity Round - Prometheus Biosciences
Eventide
Eventide investment in Private Equity Round - Prometheus Biosciences
Point72
Point72 investment in Private Equity Round - Prometheus Biosciences
Irving Investors
Irving Investors investment in Private Equity Round - Prometheus Biosciences
Perceptive Advisors
Perceptive Advisors investment in Private Equity Round - Prometheus Biosciences
Key Employee Changes
Date | New article |
---|---|
2020-08-04 | Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer |
Official Site Inspections
http://www.prometheusbiosciences.com Semrush global rank: 3.12 M Semrush visits lastest month: 4.9 K
- Host name: lax17s38-in-f14.1e100.net
- IP address: 172.217.14.78
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Prometheus Biosciences"
Prometheus Biosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 858-824-0895 Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, …See details»
Merck Completes Acquisition of Prometheus Biosciences, Inc.
Jun 16, 2023 RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus …See details»
What can we help you find? - Merck
Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»
MSD Completes Acquisition of Prometheus Biosciences, Inc.
Jun 16, 2023 Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions …See details»
Prometheus Biosciences, Inc. | LinkedIn
Prometheus Biosciences, Inc. Biotechnology Research San Diego, California 8,044 followers Revolutionizing medicine with precision.See details»
Acquisition of Prometheus Biosciences
Apr 17, 2023 charge on Prometheus Biosciences’ internet website at www.prometheusbiosciences.com or by contacting Prometheus Biosciences at 3050 Science …See details»
Prometheus Biosciences - PitchBook
Prometheus Biosciences General Information Description. Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, …See details»
Prometheus Biosciences - Craft
Jun 16, 2023 Prometheus Biosciences has 3 employees at their 1 location and $6.81 m in annual revenue in FY 2022. See insights on Prometheus Biosciences including office …See details»
Board of Directors | Prometheus Biosciences
Helen C. Adams, CPA, has been a member of our Board of Directors since February 2021. From January 2013 to March 2018, Ms. Adams was the San Diego Area Managing Partner for …See details»
Prometheus Biosciences, Inc. Announces Proposed Public Offering …
SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for …See details»
Prometheus Biosciences Announces $130 Million Financing to …
Nov 9, 2020 For more information about Prometheus, please visit www.prometheusbiosciences.com. Contacts: Investor Relations and Media Contact Juniper …See details»
Merck | Home
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.See details»
Prometheus Biosciences Achieves Milestone Payment from Dr.
-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- …See details»
Merck Strengthens Immunology Pipeline with Acquisition of
Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»
Prometheus Biosciences Reports Fourth Quarter and Full-Year …
Feb 28, 2023 Prometheus’ Phase 2 ARTEMIS-UC clinical trial was a 12-week, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of PRA023 in …See details»
Prometheus Biosciences Announces Upsized Pricing of Initial …
SAN DIEGO, March 11, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, …See details»
Merck Strengthens Immunology Pipeline with Acquisition of …
Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»
Prometheus Biosciences Reports Fourth Quarter and Full-Year
Feb 28, 2023 [email protected]. Media contact: Juniper Point Amy Conrad (858) 914-1962 [email protected]. Tags RXDX 4Q 2023 Earnings ...See details»
Prometheus Biosciences Reports First Quarter 2022 Financial …
May 12, 2022 - Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies …See details»
Prometheus Biosciences Announces Positive Results for PRA023 in …
Dec 7, 2022 – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – …See details»